FDAapproval54% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (ild) as Novartis.
Regulatory Analysis
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Supporting Context
- Therapeutic area
- Oncology · Pediatric
- Sub-indication
- Ild
Related signal: Feasibility Study on Sensory Changes in Pediatric Oncology Patients Undergoing Treatment